Zhitong Finance App News, Chuangsheng Group Pharmaceutical-B (06628.HK) announced that since the Company and Ernst & Young (EY), the Company's current auditor, failed to reach an agreement on the audit fees for the annual audit of the Group's consolidated financial statements (2026 audit) for the year ended December 31, 2026, the Group's operating scale was drastically reduced after considering the sale of CDMO assets in the second half of 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.